The Confederation joins the EU-wide Health-Technology-Assessment (HTA)
The EU Government has decided to install an EU-wide Health-Technology-Assessment (HTA). The purpose is to provide a procedure for assessing the added value, effectiveness, costs and broader impact of health care interventions, including medicines, medical devices and procedures.
For detailed information please see the links below:
https://health.ec.europa.eu/health-technology-assessment_en
https://health.ec.europa.eu/health-technology-assessment/regulation-health-technology-assessment/implementation-regulation-health-technology-assessment_en
https://health.ec.europa.eu/system/files/2023-09/hta_regulation-implementation_factsheet_en.pdf
As far as we know, there are comparable regulations and assessment-systems in all our member-countries, but all of them differ. We must be aware, that EU-regulation will be put into force from 2025.
In the fall of 2022, the EU invited among others the scientific societies to join a stakeholder network to get more information and make proposals for this new EU-HTA-system.
The CEORL took the chance to join this network, following the initiative by Thomas Deitmer from Germany. Upon request, Thomas Deitmer accepted to be the CEORL representative in the EU-HTA, along with the CEORL president.
As delegates of the CEORL, we can attend virtual or live meetings on the topic and keep you informed about details of the regulations planned.
On October, Deitmer attended an online-meeting with about 50 stakeholders. There were many stakeholders from health-technology-developers, pharmaceutical organizations and patient-organizations. Only a few scientific societies were present.
The purpose was a consultation between the stakeholders and the HTA-team of the EU-authority about aspects of an „implementing act“, that shall describe the process of HTA progress more detailed. Issues discussed were: template for the medical and pharmaceutical companies for submission, timelines, involvement of medical experts and patients view, etc. It was strengthened, that experts can best be recruited from scientific societies, as they are well informed on existing standard treatment.
Future communications from CEORL will inform you about the progress in this field, which will also be displayed on the EU-website (see above).
If you have any questions about the issue, please contact: Prof. Dr. Thomas Deitmer,
Prof. Dr. Thomas Deitmer
CEORL-HNS delegate to EU-HTA
Secretary General of the German Society of ORL-HNS
Prof. Dr. Per Cayé-Thomasen
President CEORL-HNS